Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
Type:
Application
Filed:
May 17, 2023
Publication date:
September 14, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, X1, Rx, Ry, Cy, L and R1 are as described herein, compositions including the compounds and methods of using the compounds.
Type:
Application
Filed:
May 18, 2023
Publication date:
September 14, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
Type:
Application
Filed:
May 17, 2023
Publication date:
September 14, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, X1, X2 and R1 are as described herein, compositions including the compounds and methods of using the compounds.
Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
Type:
Grant
Filed:
December 31, 2020
Date of Patent:
September 12, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Peter Hagedorn, Anja Mølhart Høg, Richard E. Olson, Marianne L. Jensen
Abstract: The disclosure relates to methods for handling and supplementation of cell culture medium to improve process performance in eukaryotic recombinant expression systems.
Type:
Application
Filed:
October 12, 2022
Publication date:
September 7, 2023
Applicants:
Hoffmann-La Roche Inc., Genentech, Inc.
Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
Type:
Application
Filed:
August 2, 2021
Publication date:
September 7, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Dongdong CHEN, Jianguo CHEN, Fabian DEY, Xin HONG, Xuefei TAN, Jiasu XU, Weixing ZHANG, Wei ZHU, Ge ZOU
Abstract: The present invention provides novel compounds having the general formula (I): wherein A, L, and B are as described herein, compositions including the compounds and methods of using the compounds.
Type:
Application
Filed:
May 16, 2023
Publication date:
September 7, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Jianping WANG, Hongying YUN, Bo ZHANG, Xiufang ZHENG
Abstract: Embodiments disclosed herein generally relate to connected machine learning models with joint training for lesion detection. Particularly, aspects of the present disclosure are directed to accessing a three-dimensional magnetic resonance imaging (MRI) image, wherein the three-dimensional MRI image depicts a region of a brain of a subject, wherein the region of the brain includes at least a first type of lesions and a second type of lesions; inputting the three-dimensional MRI image into a machine-learning model comprising a first convolutional neural network and a second convolutional neural network; generating a first segmentation mask for the first type of lesions using the first convolutional neural network that takes as input the three-dimensional MRI image; generating a second segmentation mask for the second type of lesions using the second convolutional neural network that takes as input the three-dimensional MRI image; and outputting the first segmentation mask and the second segmentation mask.
Type:
Application
Filed:
February 27, 2023
Publication date:
September 7, 2023
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC.
Inventors:
Zhuang Song, Nils Gustav Thomas Bengtsson, Richard Alan Duray Carano, David B. Clayton, Alexander James Stephen Champion De Crespigny, Laura Gaetano, Anitha Priya Krishnan
Abstract: The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a CEA CD3 bispecific antibody and a TGF? signaling inhibitor.
Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
Type:
Grant
Filed:
December 16, 2020
Date of Patent:
August 29, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Jens Fischer, Guy Georges, Anton Jochner, Gregor Jordan, Hubert Kettenberger, Joerg Moelleken, Tilman Schlothauer, Georg Tiefenthaler, Valeria Runza, Meher Majety, Martin Schaefer, Maria Viert, Shu Feng, Wei Shiong Adrian Ho, Siok Wan Gan, Runyi Adeline Lam, Michael Gertz
Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.
Type:
Grant
Filed:
March 30, 2021
Date of Patent:
August 29, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Giuseppe Cecere, Luca Gobbi, Maria-Clemencia Hernandez, Frédéric Knoflach, Andreas Koblet, Eoin Cornelius O'Connor, Andres Miguel Olivares Morales, Michael Reutlinger, Valerie Runtz-Schmitt, Jaclyn Ivy Wamsteeker Cusulin, Nicolas Zorn
Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade treatment.
Type:
Application
Filed:
October 31, 2022
Publication date:
August 24, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Christian Klein, Maud Léa Mayoux, Andreas Roller, Wei Xu
Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
Type:
Grant
Filed:
September 3, 2021
Date of Patent:
August 22, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R9 and p are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
Type:
Application
Filed:
March 6, 2023
Publication date:
August 17, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Zhanling CHENG, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Bernd PUELLMANN, Jianhua WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Type:
Application
Filed:
March 28, 2023
Publication date:
August 17, 2023
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
Inventors:
Deepak SAMPATH, Christian KLEIN, Wayne John FAIRBROTHER
Abstract: The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
Type:
Application
Filed:
February 17, 2023
Publication date:
August 17, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Dennis JUL HANSEN, Souphalone LUANGSAY, Alan James MUELLER-BRECKENRIDGE, Lykke PEDERSEN, Johanna Marie POSE VICENTE
Abstract: Herein is reported a method for selecting an antibody with a systematic clearance in cynomolgus monkeys of less than 8 mL/kg/day comprising the steps of measuring the retention time of the antibody on performing an FcRn affinity chromatography with a positive linear pH gradient and on a heparin affinity chromatography with a positive linear conductivity/salt gradient, and selecting an antibody that has a relative retention time on the FcRn affinity chromatography column is less than 1.78 times the retention time difference between peaks 2 and 3 the retention time of preparation of an oxidized anti-Her3 antibody of SEQ ID NO: 03 and 04, and a relative retention time on the heparin affinity chromatography column is less than 0.87 times the retention time of an anti-pTau antibody of SEQ ID NO: 01 and 02.
Type:
Application
Filed:
April 21, 2023
Publication date:
August 10, 2023
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Hubert Kettenberger, Wolfgang Richter, Laurent Lariviere, Thomas Kraft, Thomas Emrich